Nurix Therapeutics, Inc. $NRIX Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 1.6% in the first quarter, according to its most recent filing with the SEC. The fund owned 582,066 shares of the company’s stock after acquiring an additional 9,232 shares during the period. Charles Schwab Investment Management Inc. owned about 0.76% of Nurix Therapeutics worth $6,915,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Nurix Therapeutics by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 4,415,122 shares of the company’s stock valued at $52,452,000 after purchasing an additional 69,856 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Nurix Therapeutics during the 1st quarter valued at $169,000. XTX Topco Ltd acquired a new stake in Nurix Therapeutics during the 1st quarter valued at $222,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Nurix Therapeutics by 13.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,829 shares of the company’s stock valued at $224,000 after purchasing an additional 2,260 shares during the period. Finally, ARK Investment Management LLC raised its stake in Nurix Therapeutics by 4.0% during the 1st quarter. ARK Investment Management LLC now owns 1,590,910 shares of the company’s stock valued at $18,900,000 after purchasing an additional 60,617 shares during the period.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 5,402 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the sale, the chief financial officer owned 35,512 shares in the company, valued at approximately $391,697.36. This trade represents a 13.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 4,308 shares of the stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total transaction of $51,739.08. Following the completion of the sale, the insider owned 69,023 shares of the company’s stock, valued at approximately $828,966.23. The trade was a 5.87% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,014 shares of company stock valued at $163,014 over the last 90 days. Corporate insiders own 7.40% of the company’s stock.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $9.53 on Wednesday. The company has a market capitalization of $728.57 million, a price-to-earnings ratio of -3.65 and a beta of 2.14. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The company’s fifty day moving average price is $11.33 and its two-hundred day moving average price is $11.93.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.27. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. The company had revenue of $44,056 billion during the quarter, compared to analysts’ expectations of $16.26 million. As a group, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NRIX has been the topic of a number of research reports. HC Wainwright dropped their price target on shares of Nurix Therapeutics from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Monday, July 14th. Morgan Stanley set a $16.00 price target on shares of Nurix Therapeutics and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $27.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, April 29th. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 price target (down from $32.00) on shares of Nurix Therapeutics in a research note on Thursday, July 31st. Finally, Wall Street Zen raised shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 21st. Thirteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $28.87.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.